Related Experiment Videos
Chronic heart failure- potential for pharmacological intervention.
1Thrombosis Research Institute, Emmanuel Kaye Building, Manresa Road, Chelsea, London SW3 6LR, UK. dlorenzo@tri-london.ac.uk
Current Medicinal Chemistry. Cardiovascular and Hematological Agents
|April 28, 2005
Summary
Heart failure patients face high risks of athero-thrombotic events. Current evidence is insufficient to recommend antithrombotic therapy unless specific conditions like atrial fibrillation are present.
Area of Science:
- Cardiology
- Vascular Medicine
- Thrombosis Research
Background:
- Heart failure (HF) is frequently linked to vascular diseases and a significant risk of athero-thrombotic events.
- The precise incidence of thromboembolism in HF patients is uncertain, with estimates around 2% derived from limited studies.
- Pathophysiology involves complex factors like vascular abnormalities, hypercoagulability, and impaired blood flow in HF.
Purpose of the Study:
- To review the incidence, underlying mechanisms, and therapeutic strategies for managing thromboembolism in heart failure patients.
- To highlight the lack of robust evidence supporting routine antithrombotic therapy in HF.
- To emphasize the need for randomized clinical trials to evaluate anticoagulant benefits in chronic heart failure.
Main Methods:
- Systematic review of existing literature on thromboembolism in heart failure.
- Analysis of epidemiological data and small studies to estimate incidence.
- Examination of pathophysiological factors contributing to thrombosis in HF.
- Review of current therapeutic guidelines and expert recommendations.
Main Results:
- Thromboembolism incidence in heart failure is not well-established due to limited epidemiological data.
- Existing guidelines do not recommend antithrombotic therapy for HF patients without specific comorbidities (e.g., atrial fibrillation).
- There is a significant lack of evidence for the efficacy of antithrombotic agents in the general heart failure population.
Conclusions:
- Antithrombotic therapy for heart failure patients lacks sufficient evidence, except in cases with atrial fibrillation or prior thromboembolic events.
- Further well-designed randomized clinical trials are crucial to determine the efficacy and safety of anticoagulant therapy in chronic heart failure.
- Understanding the complex interplay of factors contributing to thrombosis in HF is essential for developing targeted therapeutic approaches.